Compounds > a-007
Page last updated: 2024-11-10

a-007

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3089902
CHEMBL ID307697
SCHEMBL ID18821
SCHEMBL ID13657372
SCHEMBL ID13657375
MeSH IDM0256742

Synonyms (32)

Synonym
a-007
sivifene
4,4'-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone
a007 ,
a 007
4,4'-dihydroxybenzophenone 2,4-dinitrophenylhydrazone
CBDIVE_002876
AKOS000528225
CHEMBL307697
D09380
sivifene (usan/inn)
2675-35-6
4-[[2-(2,4-dinitrophenyl)hydrazinyl]-(4-hydroxyphenyl)methylidene]cyclohexa-2,5-dien-1-one
sivifene [usan:inn]
methanone, bis(4-hydroxyphenyl)-, (2,4-dinitrophenyl)hydrazone
unii-xav05295i5
xav05295i5 ,
sivifene [usan]
4,4'-((2-(2,4-dinitrophenyl)hydrazinylidene)methylene)diphenol
sivifene [who-dd]
sivifene [inn]
SCHEMBL18821
SCHEMBL13657372
SCHEMBL13657375
AKOS026676522
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
4-[n-(2,4-dinitroanilino)-c-(4-hydroxyphenyl)carbonimidoyl]phenol
cid 5717660
bis(4-hydroxyphenyl)methanone (2,4-dinitrophenyl)hydrazone
DB05686
Q27293750
DTXSID30949554

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" A relative oral bioavailability factor of 2% was calculated for rats and monkeys for plasma A-007."( Comparative preclinical toxicology and pharmacology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in vitro and in rodents and primates.
Fan, D; Harrison, TJ; Morgan, LR; Ratterree, M; Rodgers, AH; Sartin, BW; Soike, K, )		0.56
" Oral bioavailability data suggests that this is not an efficient mode of drug administration and availability diminishes as one progresses from rodents to primates (relative oral bioavailability 2%); thus suggesting an alternative form of drug delivery is required in higher species."( Relative bioavailability of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rats and monkeys.
Morgan, LR; Ratteree, M; Rodgers, AH; Soike, K; Subramasnian, S, 1996)		0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID219155In vitro cytotoxicity in estrogen receptor and progesterone receptor negative Human breast tumor cells; (5+/-2, 0.2+/-0.3)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID82567Cytotoxicity in HH T-lymphocytic leukemia cells2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers.
AID90629Tested for anticancer activity against human melanoma2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts.
AID90136Tested for anticancer activity against human breast cancer2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts.
AID88857Tested for anticancer activity against human ovarian cancer2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts.
AID68950In vitro cytotoxicity in FDCP-1 cell line2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID42937Binding Intensity against CD45+ HH-leukemic cells at 5 ug/mL2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers.
AID44521Binding Intensity against CD11C+ HH-leukemic cells at 5 ug/mL2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers.
AID219888In vitro cytotoxicity in Human colon tumor cells; (>12+/-4, >12+/-5)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID94688In vitro cytotoxicity in KM 12L4 cell line; Not available2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID94683In vitro cytotoxicity in KM 12 C cell line; Not available2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID219156In vitro cytotoxicity in estrogen receptor negative progesterone receptor positive Human breast tumor cells; (3+/-2, 0.4+/-0.1)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID222164In vitro cytotoxicity in Human melanoma tumor cells; (5+/-4, >10)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID95467In vitro cytotoxicity in K 1735 M2 cell line; Not available2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID157392Tested against normal human peripheral blood dendritic cells, expressed as IC502001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts.
AID94684In vitro cytotoxicity in KM 12 SM cell line2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID219157In vitro cytotoxicity in estrogen receptor positive progesterone receptor negative Human breast tumor cells; (>5, 0.5)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID105051In vitro cytotoxicity in MDA-MB-435/lung met cell line; Not available2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID42618Binding Intensity against CD4+ HH-leukemic cells at 5 ug/mL.2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers.
AID223650In vitro cytotoxicity in Human ovary tumor cells; (3+/-3, 4.2+/-4)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID38019In vitro cytotoxicity in B 16 F10 cell line2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID146558Tested for anticancer activity against human lung cancer (NSCLC)2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts.
AID101979In vitro cytotoxicity in MDA-MB-435 cell line2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID221337In vitro cytotoxicity in Human lung tumor cells; (5+/-5, 6+/-5)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID222038In vitro cytotoxicity in estrogen receptor and progesterone receptor positive Human breast tumor cells; (2.5+/-0.9, 0.5+/-1)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
AID200306In vitro cytotoxicity in SN 12 PM6 cell line2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's9 (81.82)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.67 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index127.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (76.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		210adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
tetrodotoxin
Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.		2.0210azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
ConditionIndicatedRelationship StrengthStudiesTrials
Age-Related Memory Disorders
[description not available]		02.0210
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.0210
Cancer of Skin
[description not available]		03.4111
Skin Neoplasms
Tumors or cancer of the SKIN.		03.4111
Cortical Lewy Body Disease
[description not available]		0210
Acute Confusional Senile Dementia
[description not available]		0210
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		0210
Lewy Body Disease
A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)		0210